Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
October is Liver Cancer Awareness Month.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
Liver complications, heart disease and non-liver cancers also account for most deaths among people with hepatitis B or C.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
NAFLD is the leading indicator of mortality among Medicare beneficiaries with hepatocellular carcinoma.
The profile of chronic liver disease has changed due to obesity trends and advances in the treatment of hepatitis C.
The immunotherapy and targeted therapy combo improved both overall survival and patient-reported outcomes.
The regulatory agency requested further data to show whether its benefits outweigh its risks.
This new test could “play an important role” in screening people who are at risk for developing hepatocellular carcinoma.
A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.
Learn more about how NAFLD progresses and eventually leads to worsening liver damage.
It involves the buildup of fat in the liver.
Houstonian Terri Milton is determined not to let advanced fatty liver disease get the best of her.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.